A role for the eIF4E-binding protein 4E-T in P-body formation and mRNA decay

Maria A. Ferraiuolo,¹ Sanjukta Basak,¹ Josee Dostie,¹ Elizabeth L. Murray,² Daniel R. Schoenberg,² and Nahum Sonenberg¹

¹Department of Biochemistry, McGill University, Montréal, Québec H3G 1Y6, Canada
²Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, OH 43210

Introduction

The regulation of mRNA biogenesis and decay plays an important role in the control of gene expression. mRNA decay regulates protein levels, eliminates aberrant mRNAs, and is an essential host defense mechanism during viral infection (Coller and Parker, 2004). There are three major mRNA decay pathways (Coller and Parker, 2004; Parker and Song, 2004). The general pathway involves deadenylation followed by decapping of the mRNA. In yeast, transcripts are primarily degraded in a 5’→3’ direction by the Xrn1 exonuclease (Muhlrad et al., 1995; Schwartz and Parker, 1999; Coller and Parker, 2004; Parker and Song, 2004), whereas in higher eukaryotes, mRNAs mostly are eliminated in a 3’→5’ fashion by the exosome after deadenylation (Chen et al., 2001; Hilleren et al., 2001; Wang and Kiledjian, 2001; Wilusz et al., 2001; Mukherjee et al., 2002; Tourriere et al., 2002). mRNA degradation also can occur through a second pathway that involves endonucleolytic cleavage of mRNAs (Schoenberg and Chernokalskaya, 1997), and in addition, through specialized mechanisms, including nonsense-mediated decay and nonstop decay (for reviews see Wilusz et al., 2001; Tourriere et al., 2002; Coller and Parker, 2004; Parker and Song, 2004).

mRNA decapping is a crucial step in general and specialized mRNA decay (Parker and Song, 2004). Decapping is mediated by a heterodimeric complex composed of Dcp1 and Dcp2 (Beelman et al., 1996; Dunkley and Parker, 1999; Lykke-Andersen, 2002; van Dijk et al., 2002; Wang et al., 2002). Numerous factors that regulate decapping activity have been identified in yeast and mammals. The Lsm 1–7 complex, Pat1p, Dhh1p, Ecd1p, Ecd2, and Ecd3 are positive regulators of decapping, characterized in yeast (Coller and Parker, 2004; Parker and Song, 2004).

Most mammalian mRNAs studied are the target of degradation by the 3′→5′ exosome (Chen et al., 2001; Mukherjee et al., 2002; Wang and Kiledjian, 2001). Nonetheless, decapping activity similar in function to the yeast Dcp1p has been detected in HeLa cells (Gao et al., 2001); mammalian homologues of Dcp1/2 (Lykke-Andersen, 2002; Wang et al., 2002), the Lsm proteins (Achsel et al., 1999), and Dhh1p (Smillie and Sommerville, 2002) also exist. Furthermore, Xrn1 homologues have been identified in mammals (Bashkirov et al., 1997; Ingelfinger et al., 2002). However, it has not been demonstrated unequivocally whether deadenylated-decapped mRNAs are subject to 5′ or 3′ exonucleolytic decay in mammalian cells in vivo (discussed in Wang and Kiledjian, 2001; Mukherjee et al., 2002; Wilusz and Wilusz, 2004).
The mRNA 5′ cap structure and the 3′ polyA tail play important roles in the decapping process (Wilusz et al., 2001; Coller and Parker, 2004). The polyA inhibits decapping, likely through the polyA binding protein (PABP) interaction with eIF4G, a component of the eIF4F cap-binding complex (Coller and Parker, 2004). eIF4F also contains the cap binding protein, eukaryotic initiation factor 4e (eIF4E), and the RNA helicase, eIF4A (Gingras et al., 1999). The interaction of PABP with eIF4G enhances the binding of eIF4E to the mRNA (Kahvejian et al., 2005), and thus, hinders the access of the decapping complex to the cap. Consequently, translation and decapping are antagonistic. Consistent with this idea, mutations in eIF4E and eIF4G can lead to an increase in decapping in yeast (Schwartz and Parker, 1999). Importantly, decapping requires the removal of eIF4F from the 5′ cap structure, which, in turn, necessitates a transition from a translationally active messenger RNP (mRNP) to one destined for decay. This transition entails the replacement of initiation factors on the mRNA with decapping factors (Tharun and Parker, 2001; Coller and Parker, 2004; Parker and Song, 2004; Teixeira et al., 2005). The switch from translation to decay occurs concomitantly with aggregation of mRNPs into distinct cytoplasmic foci, termed processing bodies (P-bodies), in yeast (Sheth and Parker, 2003), or GW bodies (Eystitthiloy et al., 2003) or Dcp1a bodies in mammals (Cougot et al., 2004); these are referred to as P-bodies throughout this article. The decapping enzyme, Dcp1/2, and decapping associated factors, Lsm1-7, Dhh1p/p54, and Xrn1, are concentrated in these foci (Ingelfinger et al., 2002; van Dijk et al., 2002; Sheth and Parker, 2003; Cougot et al., 2004; Liu et al., 2004). However, little is known about the recruitment mechanism of mRNAs to P-bodies, or how initiation factors are exchanged with decapping enzymes.

We reported earlier the cloning of 4E-transporter (4E-T), which interacts with eIF4E through a conserved eIF4E recognition motif (YXXXXLΦ, where Φ is a hydrophobic amino acid) that is also found in eIF4G and 4E-BP. 4E-T is a nucleocytoplasmic shuttling protein that mediates the nuclear import of eIF4E through the importin α/β pathway. At steady state, 4E-T is predominantly cytoplasmic and is concentrated in bodies that conspicuously resemble the recently described P-bodies (Dostie et al., 2000a; Sheth and Parker, 2003). Here, we report that 4E-T colocalizes with eIF4E and decapping factors in bona fide P-bodies and controls mRNA turnover. Significantly, depletion of 4E-T from cells enhances mRNA stability.

**Results**

**4E-T colocalizes with decapping factors**

To determine whether 4E-T associates with P-bodies, the localization of 4E-T and P-body components was analyzed by immunofluorescence in HeLa cells. Cells transfected with HA–4E-T were analyzed by double-label immunofluorescence microscopy using anti-HA antibody and an affinity-purified anti-Dcp1a antibody that recognizes the endogenous protein (see Materials and methods). Transfected HA–4E-T and endogenous Dcp1a colocalized in the cytoplasm in discrete foci that strongly resemble P-bodies (Fig. 1 A). Similar results were obtained with a GFP-tagged 4E-T (Fig. 1 B). To show that endogenous 4E-T also localizes to P-bodies, its colocalization with Me31B was studied (Me31B is the Drosophila homologue of the human decapping factor Dhh1p/p54, and similar to Dcp1a, is an established marker of P-bodies [Sheth and Parker, 2003; Tseng-Rogenski et al., 2003]; Me31B shares 71% identity with Dhh1p/p54 and was shown to form cytoplasmic granules in germline cells [Nakamura et al., 2001]). HeLa cells transfected with myc-EYFP-Me31B were stained with an affinity-purified anti–4E-T antibody, and analyzed by microscopy. Endogenous 4E-T colocalizes with myc-EYFP-Me31B in discrete cytoplasmic foci (Fig. 1 C). Thus, endogenous and transfected 4E-T colocalize with bona fide decapping factors in cytoplasmic foci, which fulfill the criteria of P-bodies.

**4E-T down-regulates cap-dependent translation**

In the yeast *Saccharomyces cerevisiae*, targeting of mRNAs to P-bodies is believed to occur as a consequence of cessation of translation (Schwartz and Parker, 1999; Tharun and Parker, 2001; Teixeira et al., 2005). Thus, it is conceivable that changes in mRNP composition that lead to translational arrest result in targeting the mRNA to P-bodies in mammals. 4E-T interacts with eIF4E through a conserved binding site, which also is found in eIF4G (Mader et al., 1995), and thus, might promote targeting of mRNAs to P-bodies by inhibiting translation initiation.
tion. To address this possibility, the inhibitory effect of 4E-T on translation was examined in vivo. HeLa cells infected with recombinant vaccinia virus vTF7-3 (to synthesize the T7 RNA polymerase in the cytoplasm) were cotransfected transiently with plasmid DNA containing a 4E-T cDNA and a bicistronic reporter construct expressed from a T7 promoter. The bicistronic reporter construct consists of the luciferase (LUC) and chloramphenicol acetyl transferase (CAT) cistrons, separated by the poliovirus internal ribosome entry site (IRES; Pause et al., 1994) (Fig. 2 A). Translation of the LUC cistron proceeds in a cap-dependent manner, whereas translation of the CAT cistron is cap-independent and serves as a surrogate control for mRNA levels. (Note that quantification of the RNA by Northern blotting could not be performed because the vaccinia virus T7 system produces heterogeneous RNA transcripts, generating smeared bands [Fuerst and Moss, 1989]. This is attributed to the lack of an authentic T7 RNA polymerase termination sequence. However, this has no deleterious effect on mRNA turnover or translation [Fuerst and Moss, 1989].) Only a fraction (5–10%) of T7-transcribed RNAs are capped by the vaccinia-capping enzyme (Fuerst and Moss, 1989). However, uncapped RNA is translated inefficiently in vivo and in vitro (Both et al., 1975; Shatkin, 1976; Sonenberg et al., 1980; Fuerst and Moss, 1989; Peng and Schoenberg, 2005; and unpublished data). Thus, even if only a small fraction of the T7-transcribed RNAs is capped in the T7 vaccinia virus system, the uncapped products largely are untranslated (~0.4–1% of uncapped compared with capped RNA; unpublished data). All constructs were expressed to similar levels (Fig. 2 B, bottom panel, compare lanes 2–4). The binding of 4E-T to eIF4E was demonstrated by Far Western blotting with [32P]HMK-eIF4E (Fig. 2 B, lane 2, top panel). The 4E-T mutant, Y30A, which is mutated in the YXXXXLΦ motif, did not bind to eIF4E, as expected (Fig. 2 B, lane 3, top panel). LUC expression was decreased significantly by overexpression of wild-type 4E-T (Fig. 2 C, left, top panel), whereas CAT activity remained relatively unchanged (Fig. 2 C, left, bottom panel). In contrast, the Y30A mutant of 4E-T did not affect LUC or CAT expression. Therefore, overexpression of wild-type 4E-T, but not the mutant Y30A, strongly inhibited (88%) translation (Fig. 2 C). In conclusion, overexpression of 4E-T in HeLa cells results in the repression of translation only when bound to eIF4E.

**eIF4E localizes to P-bodies**

Because 4E-T localizes to P-bodies, and because it interacts with eIF4E, it was pertinent to ask whether eIF4E also localizes to P-bodies, and whether this localization requires 4E-T. To this end, we performed immunofluorescence analysis of endogenous eIF4E in HeLa cells using a monoclonal antibody, which recognizes eIF4E in the cytoplasm (Kimball et al., 2003). Although eIF4E is distributed throughout the cytoplasm, it is...
Figure 3. **eIF4E colocalizes with 4E-T, Dcp1a, and Dcp2 in P-bodies.**

(A) HeLa cells (CCL2) were fixed and the localization of eIF4E was determined by indirect immunofluorescence with mouse anti-eIF4E monoclonal antibody and Alexa Fluor 594 anti–mouse IgG. The localization of 4E-T was examined with anti–4E-T and that of Dcp2 with anti-Dcp2 and Alexa Fluor 488 anti–rabbit IgG. The colocalization of these factors appears yellow in the merged image.

(B) The colocalization of endogenous eIF4E with 4E-T and Dcp1a was examined with anti–4E-T and anti-Dcp1a in HeLa S3 as above. The left panel...
concentrated in foci reminiscent of P-bodies (Fig. 3 A). This staining pattern is observed in two different HeLa cell sublines: HeLa CCL2 and HeLa S3 (Carter et al., 1995), but with qualitative differences (Fig. 3, A and B–E, respectively), and in mouse embryo fibroblasts (not depicted). Furthermore, transiently transfected HA-eIF4E also displays a similar cytoplasmic distribution pattern (see below, Fig. 4 A).

Double-label immunofluorescence analysis shows that eIF4E colocalized with 4E-T and Dcp2 in P-bodies (Fig. 3 A). eIF4E exhibited a more pronounced association with P-bodies in CCL2 (Fig. 3 A) as compared with HeLa S3 (Fig. 3 B). eIF4E colocalized with Dcp1a and 4E-T in P-bodies, albeit staining of eIF4E in these structures is not as apparent as the staining of 4E-T and Dcp1a in HeLa S3 (Fig. 3 B). Strikingly, overexpression of GFP–4E-T resulted in enhanced staining of eIF4E in P-bodies (Fig. 3 C). Because localization of eIF4E in P-bodies was more prominent, and the foci appeared larger and brighter in GFP–4E-T overexpressing cells than in parental cells, these data suggest that 4E-T might tether eIF4E to P-body structures. This effect is illustrated in a graph plotting the intensity of the eIF4E signal (red channel) in two P-bodies marked by an arrow in cells overexpressing 4E-T levels (Fig. 3 D, right panel) and in cells expressing endogenous 4E-T levels (Fig. 3 D, left panel; the respective P-bodies traversed by the arrow are circled in the adjacent panel for comparison). The signal intensity of eIF4E was approximately twofold higher in cells overexpressing 4E-T as compared with endogenous 4E-T levels, when P-bodies of weaker intensity were selected from cells overexpressing 4E-T to avoid signal saturation of the plot. Similar results were obtained with a monoclonal antibody against eIF4E from Transduction Laboratories (610270), and with a monoclonal antibody (10C6), which recognizes eIF4E predominantly in the nucleus (Lejbkowicz et al., 1992; Dostie et al., 2000b; unpublished data). The enhanced eIF4E signal is not due to leakage of the FITC signal, because no significant signal was detected in the red channel when cells transfected with GFP–4E-T were stained with the secondary antibody alone (Fig. 3 E).

To determine whether the association of eIF4E with P-bodies requires its interaction with 4E-T, we performed immunofluorescence analysis using wild-type HA-eIF4E and a mutant lacking the 4E-T binding site (eIF4E W73A) (Dostie et al., 2000a). Low eIF4E cDNA amounts were transfected transiently into HeLa cells to obtain a predominantly cytoplasmic distribution pattern (see below, Fig. 4 A). eIF4E was distributed uniformly between the cytoplasm and the nucleus (Fig. 4 A). Therefore, loss of 4E-T interaction (and also interaction with eIF4G and 4E-BPs) (Mader et al., 1995) leads to deregulated cellular localization, which results in diffuse staining throughout the cell. In addition, because the HA–4E-T (Y30A) mutant, which is defective in eIF4E binding (Dostie et al., 2000a), still localizes to P-bodies, these results suggest that 4E-T is required for the association of eIF4E with P-bodies, but not vice versa (see also Fig. 5 C).
Because eIF4E is part of the heterotrimeric eIF4F complex, it was important to determine whether eIF4A and eIF4G also localize to P-bodies. Because 4E-T and eIF4E are expected to compete for binding to eIF4E, no other eIF4F complex components—with the exception of eIF4E—were expected to localize to P-bodies. To investigate this, the localization of endogenous eIF4G1 and eIF4A was studied in HeLa cells transfected with GFP-Dcp1b. Western blot analysis with anti-eIF4A, which recognizes eIF4A1 and eIF4AII (Edery et al., 1983), and anti-eIF4G1 revealed protein bands corresponding to the expected size of the proteins (Fig. 4 D). Immunofluorescence analysis with these antibodies shows that eIF4G1 and eIF4A do not localize to P-bodies because neither protein colocalizes with the P-body marker, GFP-Dcp1b (Fig. 4, B and C). Similar results were obtained using two other anti-eIF4G1 antibodies (unpublished data). Thus, eIF4E, but neither eIF4G1 nor eIF4A, localized to P-bodies in vivo. It is highly likely that eIF4GII behaves in a similar manner, because it exhibits very similar properties to eIF4G1 (Gradi et al., 1998).

Short interfering RNA against 4E-T results in decreased localization of decapping factors to mammalian P-bodies

To investigate whether 4E-T plays a role in the formation of P-bodies, cellular 4E-T protein levels were reduced by RNA interference (RNAi). Western blotting (Fig. 5 A) and immunofluorescence analysis (Fig. 5 C) demonstrate that 4E-T was reduced strongly (85%) after treatment with a short interfering RNA (siRNA) against 4E-T, but not by the corresponding inverted sequence (4E-T inverted) (Fig. 5 A). Another nonspecific siRNA that was used as a control, 4AIII inverted (Ferraioulo et al., 2004), failed to affect 4E-T protein levels (Fig. 5, A and C). 4E-T depletion caused Dcp1a and eIF4E to disperse throughout the cytoplasm and no longer concentrate in foci (Fig. 5 C; cells that were unaffected in their staining in P-bodies are those that had not taken up the siRNA against 4E-T, as confirmed by immunostaining with anti-4E-T antibody: not depicted). The disappearance of P-bodies was not observed in cells that were transfected with the nonspecific control siRNA. No changes in Ddh1p/p54, Dcp1a, and eIF4E protein levels

Figure 5. Depletion of 4E-T from HeLa cells results in disappearance of decapping factors from P-bodies. [A] HeLa cells were transfected with siRNA against 4E-T or control siRNAs (4AIII inverted or 4E-T inverted). 48 h after transfection, cells were split into chamber slides for immunofluorescence analysis [see (C)] and into a 6-cm dish for Western blot analysis. 60 h after transfection, protein cell extracts were prepared and 20 μg of extract was resolved by SDS-10% PAGE. Western blotting was performed with rabbit anti–4E-T and anti-eIF4E antibodies, or mouse anti–β-actin monoclonal antibody (Sigma-Aldrich). 4E-T levels were quantified against β-actin, which served as a loading control, and the level of protein in the negative control (4AIII inverted) transfected cells was set as 100. (B) HeLa extract (20 μg) as in (A) was resolved by 10% SDS-PAGE and Western blotting was performed with rabbit anti-Dcp1a and anti-Xenopus p54 (Xp54) antibodies, or monoclonal mouse anti-eIF4E (SK) and anti–β-actin antibodies. (C) HeLa (CCL2) cells were transfected with control siRNA (4AIII inverted) or 4E-T siRNA and indirect immunofluorescence was performed 60 h after transfection with rabbit anti–4E-T and anti-Dcp1a antibodies, or monoclonal mouse anti-eIF4E antibody. (D) HeLa S3 cells were transfected with 4E-T siRNA or control siRNA (4AIII inverted). 24 h after transfection, cells were transfected with myc-EYFP-Me31B; 36 h later, extracts were collected for SDS-PAGE analysis or fixed for immunofluorescence. Cell extracts were resolved by 10% SDS-PAGE and Western blot analysis with rabbit anti–4E-T, or monoclonal anti-myc (9E10) and anti–β-actin was performed. Indirect immunofluorescence was performed to assess the localization of 4E-T, and the localization of myc-EYFP-Me31B was assessed by direct immunofluorescence. The right most panels show the enlarged bordered image.
occurred in 4E-T–depleted cells as compared with nonspecific siRNA controls (Fig. 5, A and B).

The effect of 4E-T depletion on Me31B localization also was examined (Fig. 5 D). The tagged version of Drosophila Me31B was used because the antibody against endogenous p54, used in Fig. 5 B for Western analysis, is not suitable for immunofluorescence. HeLa cells transfected with 4E-T or control siRNAs were transfected with the myc-EYFP-Me31B plasmid, and analyzed by Western blotting and double label immunofluorescence (Fig. 5 D). 4E-T levels were reduced efficiently in 4E-T siRNA-treated cells, and the myc-EYFP-Me31B protein was expressed in cells treated with control or 4E-T siRNAs (left panel). In control cells, myc-EYFP-Me31B was predominantly cytoplasmic and concentrated in P-bodies (right panel). However, when 4E-T levels were reduced, Me31B exhibited a diffuse staining pattern throughout the cytoplasm and reduced or no staining in P-bodies (right panel). Thus, reduction of 4E-T protein levels causes mislocalization of eIF4E and decapping factors away from P-bodies.

Cycloheximide inhibits localization of 4E-T to P-bodies, whereas leptomycin B treatment does not affect its localization

In yeast and mammalian cells, cycloheximide treatment releases decapping factors from P-bodies (Sheth and Parker, 2003; Cougot et al., 2004). Cycloheximide inhibits mRNA translation at the elongation step, which prevents mRNA degradation because of its protection by ribosomes (Ross, 1995). To study whether 4E-T localization to P-bodies is dependent on mRNA availability, the effect of cycloheximide on the localization of 4E-T was examined. HeLa cells were treated with cycloheximide (10 μg/ml), and analyzed by immunofluorescence with anti-Dcp1a and anti–4E-T antibodies. A near complete loss of 4E-T and Dcp1a from P-bodies was observed after 30 min of cycloheximide treatment (Fig. 6 A); this suggested that the accumulation of 4E-T in P-bodies is dependent on mRNA availability. This effect is not due to a reduction in 4E-T protein levels. Western blot analysis demonstrates that the levels of 4E-T and Dcp1a remain unchanged throughout the cycloheximide treatment (Fig. 6 B). Similar results were obtained in HeLa cells that were transfected transiently with HA-4E-T (Fig. 6 C, middle panel).

Leptomycin B (LMB) is an inhibitor of chromosome region maintenance-1–dependent protein nuclear export. We previously reported that 4E-T is a shuttling protein that exits the nucleus through the chromosome region maintenance-1 pathway (Dostie et al., 2000a). Because Dhh1p/p54 also shuttles between the nucleus and the cytoplasm (Smillie and Sommerville, 2002), it is possible that nuclear export is required for the localization of 4E-T and decapping factors to P-bodies. To test this hypothesis, the effect of LMB on the localization of 4E-T and Dcp1a to P-bodies was studied. LMB treatment resulted in the accumulation of 4E-T in the nucleus, but did not affect its association with P-bodies (Fig. 6 C, middle panel). The distribution of Dcp1a also was unaffected by the drug (bottom panel). Thus, the presence of 4E-T in P-bodies is dependent on mRNA, but is independent of its nucleocytoplasmic shuttling.

4E-T knockdown increases mRNA half-life

The results described above suggest that 4E-T might play a role in promoting mRNA degradation. To test this hypothesis, we analyzed the turnover of several mRNAs in 4E-T–depleted and

![Figure 6](https://example.com/image.png)

**Figure 6.** Effect of cycloheximide and LMB on 4E-T localization in P-bodies. (A) HeLa cells were treated with cycloheximide (CHX; 10 μg/ml) for 30 min, and immunofluorescence staining of 4E-T and Dcp1a were examined as described above. (B) HeLa cell extract [20 μg] treated with cycloheximide (CHX; 10 μg/ml) for 30 and 60 min was resolved by 10% SDS-PAGE and Western blot analysis with rabbit anti–4E-T and anti-Dcp1a, or monoclonal mouse β-actin was performed. (C) HeLa cells were transfected with HA–4E-T. 36 h after transfection, the medium was replaced with fresh medium (control) or medium containing CHX [100 μg/ml], and cells were incubated for 3 h before fixation. Alternatively, media containing LMB (5 ng/ml) was added to cells and incubated for 5 h before fixation. The colocalization of HA–4E-T was determined by indirect immunofluorescence with anti-HA (Covance) and that of Dcp1a with anti-Dcp1a antibody as described above. The colocalization of HA–4E-T and Dcp1a appears yellow.
control cells. A β-globin reporter that is under the control of a tetracycline-responsive promoter was fused at its 3’ end to one of two distinct adenine/uridine rich elements (AREs) (Stoecklin et al., 2004), GM-CSF or c-fos. The reporter gene—either lacking or containing the ARE—was cotransfected with a plasmid encoding the activator of transcription (pTet-Off) into HeLa cells that were transfected previously with 4E-T or control siRNA. Doxycycline was added to block transcription and RNA was collected at the indicated times and analyzed by Northern blotting. As expected, β-globin lacking an ARE remained stable throughout the doxycycline treatment, whereas β-globin containing the GM-CSF or c-fos AREs were degraded rapidly, as was reported previously (Chen et al., 1995) (Fig. 7, A and B). However, 4E-T diminution in HeLa cells resulted in significant stabilization (>2-fold) of β-globin/GM-CSF and β-globin/c-fos ARE-containing mRNA, with no effect on β-globin reporter mRNA lacking an ARE (Fig. 7, A and B). Western blot analysis demonstrates that 4E-T protein levels were diminished efficiently in HeLa cells that were transfected with the reporter plasmids and in the presence of doxycycline (Fig. 7 C). The effect of 4E-T depletion on endogenous c-fos mRNA turnover also was analyzed. Similar to transfected β-globin containing the destabilizing element of c-fos, endogenous c-fos was stabilized in the absence of 4E-T (unpublished data).

The stability of the labile p21 mRNA, which contains an ARE (Lal et al., 2004), also was examined in 4E-T-depleted cells. Western blotting analysis demonstrates that 4E-T RNAi strongly reduced the amount of 4E-T (>80%, Fig. 7 D). p21 mRNA stability was determined by Northern blot analysis after actinomycin D treatment to inhibit de novo transcription.

Figure 7. siRNA-mediated depletion of 4E-T affects mRNA turnover. HeLa cells were transfected with siRNA against 4E-T or a control [Ctrl] siRNA (4AIII inverted). Protein and RNA were harvested for use in Western (C and D) and Northern (A, B, and E) analysis, respectively. (A and B) HeLa cells were transfected with siRNA against 4E-T or with control siRNA and later cotransfected with pTet-β-globin or pTet-β-globin c-fos or GM-CSF ARE and pTet Off. Cells were treated with doxycycline [1 μg/ml] ~72 h after transfection to block transcription. Total RNA was isolated at 0.5, 2, 3, and 4 h for β-globin/GM-CSF ARE assays (A) and 0.5, 1.5, 3, and 6 h for β-globin/c-fos ARE assays (B) and analyzed by Northern blot. GAPDH served as a loading control. mRNA half-lives were calculated from Northern blots and normalized against GAPDH levels. (C) Protein extracts were collected at 6 h after treatment with doxycycline [1 μg/ml] from cells that were transfected with the reporter plasmid and pTetOff and resolved by SDS-PAGE. Lanes 1 and 4: glo pTetOff; lanes 2 and 5: fos pTetOff; lanes 3 and 6: GM pTetOff. (D) Protein extracts were collected at the latest time point of actinomycin D treatment and resolved by 10% SDS-PAGE. Western blot analysis was done with anti–4E-T and anti–β-actin antibodies. NT = nontransfected. (E) At 48 h after transfection, the half-lives of p21 mRNA were assessed by using actinomycin D [5 μg/ml] for the indicated amount of time. Total RNA [5 μg] was resolved on 1.3% formaldehyde gel and analyzed by Northern blotting. 28S levels and 18S levels served as a loading marker. mRNA half-lives were calculated from Northern blots and normalized against 32P-labeled 18S levels and plotted on a graph with the zero time point set at 100.
p21 mRNA levels were quantified in cells that were treated with 4E-T siRNAs and in nondepleted cells, and normalized to 18S rRNA levels (Fig. 7 E). 4E-T depletion resulted in a moderate (~1.5 fold), but significant, increase in the mRNA half-life (Fig. 7 E). The difference in p21 mRNA stability achieved with 4E-T depletion is related inversely to that obtained when the mRNA stabilizer, HuR, is depleted from cells (~2-fold decrease; Lal et al., 2004). Thus, 4E-T promotes degradation of mRNAs that contain an ARE in their 3’ untranslated region.

**Discussion**

Here we report a new role for 4E-T in mammalian mRNA degradation. We demonstrate that 4E-T inhibits translation, colocalizes with decapping factors in cytoplasmic P-bodies, and decreases mRNA stability. 4E-T interacts with eIF4E through a shared recognition motif (YXXXXL) also found in eIF4G (Dostie et al., 2000a). Similar to other cap-dependent translation inhibitors, 4E-T is likely to inhibit translation by competing with eIF4G for binding to eIF4E and preventing formation of the eIF4F complex (Pause et al., 1994; Poulin et al., 1998). Accordingly, overexpression of 4E-T wt, but not of a mutant defective in eIF4E binding, strongly inhibited cap-dependent translation of a reporter mRNA in vivo (Fig. 2).

The transition of an mRNA from a translationally active mRNP to one destined for decay is believed to be a consequence of translational inhibition, especially in yeast (Tharun and Parker, 2001; Teixeira et al., 2005). Remarkably, 4E-T is present in P-bodies, which are cytoplasmic foci containing factors involved in mRNA decay (Ingelfinger et al., 2002; van Dijk et al., 2002; Sheth and Parker, 2003; Cougot et al., 2004; Liu et al., 2004) (Fig. 1). In this study, we also show that eIF4E is localized to mammalian P-bodies (Fig. 3). Overexpression of 4E-T in HeLa cells caused a marked increase of eIF4E in P-bodies (Fig. 3). This observation suggests that translation inhibition and targeting of eIF4E to P-bodies are causally related. The accumulation of eIF4E in P-bodies requires interaction with 4E-T, because an eIF4E mutant that fails to bind to 4E-T cannot localize to P-bodies (Fig. 4), and depletion of 4E-T resulted in loss of eIF4E from P-bodies (Fig. 5). However, the localization of 4E-T to P-bodies does not require interaction with eIF4E, because a 4E-T mutant defective in binding to eIF4E also localizes to P-bodies (Fig. 4).

eIF4GI and eIF4A did not localize to mammalian processing bodies (Fig. 4), which is in agreement with studies that demonstrated that mRNA pools from P-bodies are distinct from translating pools (Schwartz and Parker, 1999; Tharun and Parker, 2001; Teixeira et al., 2005). These observations favor a model whereby translation inhibition that results from disruption of the translation initiation complex occurs outside P-bodies, and precedes P-body formation.

As was shown for Dcp1a (Sheth and Parker, 2003; Cougot et al., 2004), cycloheximide treatment of HeLa cells reduced the amount of 4E-T associated with P-bodies (Fig. 6). This result indicates that ongoing mRNA translation regulates the association of 4E-T with P-bodies, and suggests that 4E-T is not a permanent P-body constituent, but rather localizes to these structures in an mRNA-dependent manner. Importantly, 4E-T RNAi treatment results in decreased decapping activity in HeLa cells as evidenced by diminished localization of Dcp1a and p54 to P-bodies. Taken together, these data support a model whereby interaction of 4E-T with eIF4E acts as a priming event that leads to mRNP remodeling and mRNA decay.

In addition to their role in mRNA decay, P-bodies were suggested to function as mRNA storage sites (Sheth and Parker, 2003; Coller and Parker, 2004). For example, the *Drosophila* decapping factor Me31B, is concentrated in cytoplasmic granules in germ line cells where *bicoid* and *oskar* mRNAs are translationally masked (Nakamura et al., 2001). In addition, the *Xenopus* equivalent, Xp54, is a major constituent of maternal mRNA storage particles where translation is repressed (Ladomery et al., 1997; Minshall and Standart, 2004). Thus, it is possible that under certain conditions, the presence of eIF4E within P-bodies might permit the transition of a translationally repressed/stored mRNA to a translationally competent state.

Homology searches using Blast algorithms failed to identify 4E-T yeast homologues (Dostie et al., 2000a), and eIF4E was shown not to localize to P-bodies in yeast (unpublished data). Therefore, 4E-T might represent a more evolutionarily complex mRNA decay/storage regulation pathway in higher eukaryotes. The *Drosophila* 4E-T homologue, Cup, was reported to mediate translational repression of *nanos* and *oskar* by interacting with eIF4E and 3’ trans-acting factors (Wilhelm and Smibert, 2005). Interestingly, the RNA-binding protein Smaug, which interacts with Cup, recently was shown to recruit the CCR4 deadenylase complex in *Drosophila* embryos (Sometok et al., 2005).

An important finding in this paper is that reduction in 4E-T results in an increase in mRNA stability (Fig. 7). All of the mRNAs tested here are ARE-containing mRNAs, which are believed to be subject to 3’-5’ degradation by the exosome, based on in vitro decay assays (Chen et al., 2001; Mukherjee et al., 2002). The major deadenylase of AU-containing mRNAs in mammalian cells is believed to be poly (A) ribonuclease (Gao et al., 2000; Lai et al., 2003). Therefore, 3’-5’ degradation would require destabilization of the interaction between PABP and eIF4G to allow entry and association of poly (A) ribonuclease with the cap (Witusz et al., 2001). Therefore, 4E-T may instigate the dissociation of PABP from eIF4G by binding to eIF4E and displacing eIF4G. The decay machinery, which processes mRNA through the 5’-3’ exonucleolytic pathway, is present in P-bodies. Recent studies have implied that the 5’-3’ and 3’-5’ pathways converge at these sites. For instance, mRNA decay enzymes involved in 5’-3’ and 3’-5’ decay are recruited by the ARE binding proteins, tristetraprolin and butyrate response factor (Lykke-Anderson and Wagner, 2005). Moreover, tristetraprolin, which mediates ARE degradation by recruiting the exosome (Chen et al., 2001), also is found localized in P-bodies (Kedersha et al., 2005). Because the disappearance of P-bodies with 4E-T RNAi was not synonymous with complete stabilization of p21 mRNA, it is possible that this process occurs outside of P-bodies or that its deadenylation/decay occurs by way of a distinct pathway from *c-fos* and GM-CSF mRNAs.
In conclusion, the interaction of 4E-T with eIF4E in cells has two consequences: import of eIF4E to the nucleus (Dostie et al., 2000a) and the targeting of eIF4E to sites of mRNA decay. The function of eIF4E in the nucleus is under investigation; a proposed nuclear function of eIF4E is to export a subset of mRNAs from the nucleus (Lai and Borden, 2000; Rousseau et al., 1996). The dual role of 4E-T also might serve to sequester the limiting factor in translation initiation, eIF4E, as a means of maintaining translational homeostasis. It will be important to examine how 4E-T is regulated. It is reported that 4E-T is a phosphoprotein (Pyronnet et al., 2001); therefore, it would be interesting to know what pathways regulate its phosphorylation and activity.

While this paper was under review, two reports were published which demonstrated that eIF4E is found in P-bodies (Andrei et al., 2005; Kedersha et al., 2005), and that 4E-T is also concentrated in P-bodies (Andrei et al., 2005).

Materials and methods

Plasmids and cell culture

HA-4E-T, HA-4E-T (Y30A), HA-eIF4E, HA-eIF4E (W73A) (Dostie et al., 2000a), and pFRED143 (Cougnet et al., 2004) were digested previously. GFP-4E-T was generated by subcloning the coding region of 4E-T from pcDNA3-4E-T (Dostie et al., 2000a) into pFRED143 (provided by G. Pavlakis, National Cancer Institute, Frederick, MD). Myc-EFP-Me31B plasmid was a gift from A. Nakamura (University of Tsukuba, Tsukuba, Japan).

Construction of tetracycline-regulated β-globin expression plasmids

The starting plasmid, CMV-glo-SPA, which contains the human β-globin gene with the 5′ untranslated region and polyadenylation site replaced with a multiple cloning site and a strong synthetic polyadenylation element (SPA), was described previously (Das Gupta et al., 1998). The first generation tetracycline-regulated globin construct pTet-O-βAc-glo-SPA was prepared by digesting CMV-glo-SPA with HindIII, end-filling with Klenow fragment DNA polymerase, then digesting with NcoI. The globin-SPA fragment was gel purified and cloned into pGTEtQIALucI3 (provided by J. Garcia-Sanz, Universidad Autònoma, Madrid, Spain) in which the LUC insert was removed by digesting with BamHI, followed by end-filling with Klenow fragment DNA polymerase plus digestion with NcoI. The c-fos ARE was recovered from the plasmid pBBB-AREfos (provided by A.-B. Shyu, University of Texas Medical School, Houston, TX) by PCR amplification with primers BBARE1 (5′-CGGCTCTAGAG-GAGGCTGTGCCTGTG-3′) and BBARE2 (5′-GCGGTCGACT-CAGGAGGCATCTAGATGTC-3′). The GM-CSF ARE was recovered similarly by PCR from pBBB-AREGMCS (provided by J. Lykke-Andersen, University of Colorado, Boulder, CO), and anti-Dcp2 (1:20) (Liu et al., 2004) antibodies, or monoclonal anti-eIF4A (1:100) (Edery et al., 1983), anti-eIF4E (1:10) (Kimball et al., 2003), and anti-HA (1:1,000) (Covance) antibodies for 2 h at RT. Cells were washed extensively and incubated with Texas red or AlexaFluor 488 or 594 conjugated secondary antibody (1:200) (Molecular Probes) and anti–4E-T (1:100) (Dostie et al., 2000a), affinity-purified rabbit anti-Dcp1α (1:200) (a gift from J. Lykke-Andersen, University of Colorado, Boulder, CO), and anti-Dcp2 (1:20) (Liu et al., 2004) antibodies, or monoclonal anti-eIF4A (1:100) (Edery et al., 1983), anti-eIF4E (1:10) (Kimball et al., 2003), and anti-HA (1:1,000) (Covance) antibodies for 2 h at RT. Cells were subjected to western blotting.

Vaccinia virus infection, Far Western analysis, and translation assay

HeLa cells (80% confluence) were infected with recombinant vaccinia virus for 1 h at 37°C (Fuerst et al., 1986). Cells were rinsed once with serum-free media and transfected with 5 μg each of the reporter plasmid (pGEM-LUC-POLIRES-CAT) and pcDNA3–4E-T wt or mutant constructs using lipofectin (15 μg/ml). RNA was resolved on a formaldehyde gel as described previously (Dostie et al., 2000a). In brief, cells were plated onto Lab-Tek chambers and transfected by the calcium phosphate method as described previously (Dostie et al., 2000a). HeLa cells were transfected at 50% confluence with 5 μg (or 8 μg for GFP-4E-T) of plasmid DNA, and were processed 36 h after transfection. For transfection of myc-EFP-Me31B (Fig. 5 D), siRNA transfections were performed in 6-well plates as described above; after 24 h, 2 μg of myc-EFP-Me31B was transfected by the calcium phosphate method. 48 h after siRNA transfection, cells were trypsinized into chamber slides and processed for immunofluorescence 12 h later. Immunofluorescence was performed as described previously (Dostie et al., 2000a). In brief, cells were plated onto Lab-Tek chamber slides (Nunc) 16 h before fixation. Cells were fixed with formaldehyde, permeabilized, blocked, and incubated with affinity-purified rabbit anti–4E-T (1:100) (Dostie et al., 2000a), affinity-purified rabbit anti-Dcp1α (1:200) (a gift from J. Lykke-Andersen, University of Colorado, Boulder, CO), and anti-Dcp2 (1:20) (Liu et al., 2004) antibodies, or monoclonal anti-eIF4A (1:100) (Edery et al., 1983), anti-eIF4E (1:10) (Kimball et al., 2003), and anti-HA (1:1,000) (Covance) antibodies for 2 h at RT. Cells were subjected to western blotting.

Northern blotting

For Northern blots, cells were washed twice with ice cold PBS and pelleted at maximum speed for 10 min in a microcentrifuge. Cell pellets were frozen on dry ice and thawed in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1% Nonidet P-40, 0.5% SDS, and a mixture of protease inhibitors [Roche Diagnostics]). Extracts were incubated on ice for 10 min and centrifuged for 5 min at maximum speed to recover the supernatant. Proteins were resolved by SDS/PAGE, transferred to nitrocellulose membrane, blocked, and incubated with rabbit anti–4E-T (1:1,000) (Dostie et al., 2000a), anti-Dcp1α (1:1,000), anti-Xp54 (1:2,000) (Smillie and Sommerville, 2002), and anti-eIF4E (1:100) (Frederickson et al., 1991) polyclonal antibodies or monoclonal anti-eIF4A (1:1,000) (Edery et al., 1983), anti-4E-T (1:100) (Kimball et al., 2003), and anti-HA (1:2,000) (Covance), and anti-phospho-eIF4E (1:5,000) (Sigma-Aldrich) antibodies.

Northern blotting

Total RNA was isolated using a QIAGEN RNeasy kit according to the manufacturer’s instructions. 5 μg of total RNA was separated on a 1.3% agarose/formaldehyde gel, transferred to a Hybond-N membrane (GE Healthcare), and probed with 32P-labeled, random-primer DNA probe to detect p21 (Ial et al., 2004) or 32P-labeled oligoalkotamide, using terminal deoxynucleotidyl transferase to detect 18S RNA (Ial et al., 2004). For β-globin reporter assays, 4ET or control siRNA was transfected into HeLa cells as described above. 36 h later, pTet-β-globin reporter plasmids and pTet Off (encoding for tTA, transactivator) were cotransfected. 12 h later, cells were split 1:6 and treated 16 to 20 h later with doxycycline (1 μg/ml). RNA was resolved on a formaldehyde gel as above and probed with 32P-labeled, random-primer DNA probe to detect β-globin (Stoecklin et al., 2004) or GAPDH.

We thank H. Imataka for providing unpublished data. We thank J. Lykke-Andersen for anti-Dcp1α, M. Kiledjian (Rutgers University, Piscataway, NJ) for anti-4E-T (1:100) (Dostie et al., 2000a), and anti-Dcp2 (1:20) (Liu et al., 2004) antibodies, or monoclonal anti-eIF4A (1:100) (Edery et al., 1983), anti-eIF4E (1:10) (Kimball et al., 2003), and anti-HA (1:1,000) (Covance) antibodies for 2 h at RT. Cells were subjected to western blotting.

Downloaded from jcb.rupress.org on July 14, 2017
anti-Dcp2. S. Kimball (The Pennsylvania State University College of Medicine, Hershey, PA) for monoclonal anti-tetR2. H. Trachsel (University of Berne, Berne, Switzerland) for anti-tetR4A, and J. Sommerville (University of St. Andrews, St. Andrews, Scotland) and N. Standart (University of Cambridge, Cambridge, England) for anti-Xps4 antibodies. We are grateful to B. Seraphin (Centre Nationale de la Recherche Scientifique, Gif-sur-Yvette, France) for GFP-Dcp1b plasmid, A. Nakanuma for myc-EYFP/eGFP31B plasmid, and M. Gorospe (National Institutes of Health, Bethesda, MD) for p21 and 1BS oligomers. We thank J. Garcia-Sanz for pTetQcApluc3, and A.B. Shyu for pBBB+ARE-2 plasmids, respectively. We thank I. Gallouzi, F. Tremblay, and P. Cho for critical reading of the manuscript, and J.ballbrite for technical support with the confocal microscopy. We are indebted to C. Uister and S. Perreault for assistance.

This research was supported by a grant from the Canadian Institute of Health Research (CIHR) and U.S. Public Health Service [PHS] grants GM38277 and GM55407 to D.R. Schoenberg. E.L. Murray was supported by PHS grant T32 CA09238. N. Sonenberg is a CIHR distinguished scientist and a Howard Hughes Medical Institute International Scholar.

Submitted: 7 April 2005
Accepted: 5 August 2005

References


A ROLE FOR 4E-T IN mRNA DECAY • FERRAIUOLO ET AL.